These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 30220547)

  • 1. Corrigendum to "Efficacy and safety of biologics targeting IL-17 and IL-23 in the treatment of moderate-to-severe plaque psoriasis: A systematic review and meta-analysis of randomized controlled trials" [Int. Immunopharmacol. 62 (2018) 46-58].
    Cui L; Chen R; Subedi S; Yu Q; Gong Y; Chen Z; Shi Y
    Int Immunopharmacol; 2018 Nov; 64():432. PubMed ID: 30220547
    [No Abstract]   [Full Text] [Related]  

  • 2. Efficacy and safety of biologics targeting IL-17 and IL-23 in the treatment of moderate-to-severe plaque psoriasis: A systematic review and meta-analysis of randomized controlled trials.
    Cui L; Chen R; Subedi S; Yu Q; Gong Y; Chen Z; Shi Y
    Int Immunopharmacol; 2018 Sep; 62():46-58. PubMed ID: 29990694
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of biologics in the treatment of moderate-to-severe plaque psoriasis: a systematic review and meta-analysis of randomized controlled trials with different time points.
    Puig L; López A; Vilarrasa E; García I
    J Eur Acad Dermatol Venereol; 2014 Dec; 28(12):1633-53. PubMed ID: 24033851
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term safety of biologics in the treatment of moderate-to-severe plaque psoriasis: review of current data.
    Rustin MH
    Br J Dermatol; 2012 Nov; 167 Suppl 3():3-11. PubMed ID: 23082810
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A systematic review and meta-analysis of the efficacy and safety of the interleukin (IL)-12/23 and IL-17 inhibitors ustekinumab, secukinumab, ixekizumab, brodalumab, guselkumab and tildrakizumab for the treatment of moderate to severe plaque psoriasis.
    Bilal J; Berlinberg A; Bhattacharjee S; Trost J; Riaz IB; Kurtzman DJB
    J Dermatolog Treat; 2018 Sep; 29(6):569-578. PubMed ID: 29532693
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and tolerability of biologic and nonbiologic systemic treatments for moderate-to-severe psoriasis: meta-analysis of randomized controlled trials.
    Schmitt J; Zhang Z; Wozel G; Meurer M; Kirch W
    Br J Dermatol; 2008 Sep; 159(3):513-26. PubMed ID: 18627372
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of systemic treatments for moderate-to-severe psoriasis: meta-analysis of randomized controlled trials.
    Schmitt J; Rosumeck S; Thomaschewski G; Sporbeck B; Haufe E; Nast A
    Br J Dermatol; 2014 Feb; 170(2):274-303. PubMed ID: 24131260
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of biologics in the treatment of moderate to severe psoriasis: a network meta-analysis of randomized controlled trials.
    Reich K; Burden AD; Eaton JN; Hawkins NS
    Br J Dermatol; 2012 Jan; 166(1):179-88. PubMed ID: 21910698
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Guselkumab for the treatment of moderate-to-severe plaque psoriasis.
    Yang EJ; Sanchez IM; Beck K; Sekhon S; Wu JJ; Bhutani T
    Expert Rev Clin Pharmacol; 2018 Apr; 11(4):333-344. PubMed ID: 29478344
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of interleukin-17 antagonists in patients with plaque psoriasis: a meta-analysis from phase 3 randomized controlled trials.
    Wu D; Hou SY; Zhao S; Hou LX; Jiao T; Xu NN; Zhang N
    J Eur Acad Dermatol Venereol; 2017 Jun; 31(6):992-1003. PubMed ID: 28107570
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of tofacitinib for moderate-to-severe plaque psoriasis: a systematic review and meta-analysis of randomized controlled trials.
    Kuo CM; Tung TH; Wang SH; Chi CC
    J Eur Acad Dermatol Venereol; 2018 Mar; 32(3):355-362. PubMed ID: 29136293
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Advancements in the treatment of psoriasis: role of biologic agents.
    Rich SJ; Bello-Quintero CE
    J Manag Care Pharm; 2004; 10(4):318-25. PubMed ID: 15298530
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Systematic review of interleukin-12, interleukin-17, and interleukin-23 pathway inhibitors for the treatment of moderate-to-severe chronic plaque psoriasis: ustekinumab, briakinumab, tildrakizumab, guselkumab, secukinumab, ixekizumab, and brodalumab.
    Tausend W; Downing C; Tyring S
    J Cutan Med Surg; 2014; 18(3):156-69. PubMed ID: 24800703
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Formulary review of 2 new biologic agents: tocilizumab for rheumatoid arthritis and ustekinumab for plaque psoriasis.
    Schafer JA; Kjesbo NK; Gleason PP
    J Manag Care Pharm; 2010; 16(6):402-16. PubMed ID: 20635831
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Spotlight on brodalumab in the treatment of moderate-to-severe plaque psoriasis: design, development, and potential place in therapy.
    Roman M; Chiu MW
    Drug Des Devel Ther; 2017; 11():2065-2075. PubMed ID: 28744098
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A review article on brodalumab in the treatment of moderate-to-severe plaque psoriasis.
    Roostaeyan O; Kivelevitch D; Menter A
    Immunotherapy; 2017 Sep; 9(12):963-978. PubMed ID: 28879789
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Physician Global Assessment (PGA) and Psoriasis Area and Severity Index (PASI): why do both? A systematic analysis of randomized controlled trials of biologic agents for moderate to severe plaque psoriasis.
    Robinson A; Kardos M; Kimball AB
    J Am Acad Dermatol; 2012 Mar; 66(3):369-75. PubMed ID: 22041254
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sequential use of biologics in the treatment of moderate-to-severe plaque psoriasis.
    Leman J; Burden AD
    Br J Dermatol; 2012 Nov; 167 Suppl 3():12-20. PubMed ID: 23082811
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systematic review of UV-based therapy for psoriasis.
    Almutawa F; Alnomair N; Wang Y; Hamzavi I; Lim HW
    Am J Clin Dermatol; 2013 Apr; 14(2):87-109. PubMed ID: 23572293
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Short-term efficacy and safety of new biological agents targeting the interleukin-23-T helper 17 pathway for moderate-to-severe plaque psoriasis: a systematic review and network meta-analysis.
    Gómez-García F; Epstein D; Isla-Tejera B; Lorente A; Vélez García-Nieto A; Ruano J
    Br J Dermatol; 2017 Mar; 176(3):594-603. PubMed ID: 27292159
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.